BIT 225

Drug Profile

BIT 225

Alternative Names: BIT-225; BIT225-009

Latest Information Update: 31 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Biotron
  • Class Antivirals; Guanidines; Naphthalenes; Pyrazoles; Small molecules
  • Mechanism of Action Hepatitis C virus p7 protein inhibitors; Hepatitis C virus replication inhibitors; HIV replication inhibitors; Human immunodeficiency virus 1 vpu protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Hepatitis C

Highest Development Phases

  • Phase II Hepatitis C; HIV infections; HIV-1 infections

Most Recent Events

  • 30 Aug 2017 Pharmacodynamics data in HIV-1 infection released in Biotron's Year end final report
  • 27 Jul 2017 Biotron completes enrolment in its phase II trial for HIV-1 infections in Thailand
  • 13 Feb 2017 Phase-II clinical trials in HIV-1 infections (Treatment-naive, Combination therapy) in Thailand (PO, Capsule) (ACTRN12617000025336)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top